Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice

Alonso, 2011, Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 2946, 10.1161/CIRCULATIONAHA.111.020982 Bonde, 2016, Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study, Stroke, 47, 2707, 10.1161/STROKEAHA.116.014422 2013, Kidney Int Suppl, 3, 5, 10.1038/kisup.2012.77 Keith, 2004, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization, Arch Intern Med, 164, 659, 10.1001/archinte.164.6.659 Soliman, 2010, Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC), Am Heart J, 159, 1102, 10.1016/j.ahj.2010.03.027 Olesen, 2012, Stroke and bleeding in atrial fibrillation with chronic kidney disease, N Engl J Med, 367, 625, 10.1056/NEJMoa1105594 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Capodanno, 2012, Antithrombotic therapy in patients with chronic kidney disease, Circulation, 125, 2649, 10.1161/CIRCULATIONAHA.111.084996 Själander, 2014, Atrial fibrillation patients do not benefit from acetylsalicylic acid, Europace, 16, 631, 10.1093/europace/eut333 Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4 Hindricks, 2020, Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 Brieger, 2018, National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018, Heart Lung Circ, 27, 1209, 10.1016/j.hlc.2018.06.1043 Yang, 2017, Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease, Heart, 103, 818, 10.1136/heartjnl-2016-309266 Ha, 2019, Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 171, 181, 10.7326/M19-0087 Knauf, 2013, Dabigatran and kidney disease: a bad combination, Clin J Am Soc Nephrol, 8, 1591, 10.2215/CJN.01260213 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Chang, 2016, Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban, J Clin Pharmacol, 56, 637, 10.1002/jcph.633 Dias, 2016, Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis, Am J Nephrol, 43, 229, 10.1159/000445328 Hohnloser, 2012, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial, Eur Heart J, 33, 2821, 10.1093/eurheartj/ehs274 Hijazi, 2016, Efficacy and Safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial, JAMA Cardiol, 1, 451, 10.1001/jamacardio.2016.1170 Yao, 2017, Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction, J Am Coll Cardiol, 69, 2779, 10.1016/j.jacc.2017.03.600 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Fox, 2011, Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment, Eur Heart J, 32, 2387, 10.1093/eurheartj/ehr342 Fordyce, 2016, On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin, Circulation, 134, 37, 10.1161/CIRCULATIONAHA.116.021890 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 Stanifer, 2020, Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease, Circulation, 141, 1384, 10.1161/CIRCULATIONAHA.119.044059 Weir, 2020, Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease, Am Heart J, 223, 3, 10.1016/j.ahj.2020.01.010 Randhawa, 2020, Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis, JAMA Netw Open, 3, e202175, 10.1001/jamanetworkopen.2020.2175 Peeters, 2018, Vitamin K antagonists, non-vitamin k antagonist oral anticoagulants, and vascular calcification in patients with atrial fibrillation, TH Open, 2, e391, 10.1055/s-0038-1675578 Shen, 2015, Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation, Am J Kidney Dis, 66, 677, 10.1053/j.ajkd.2015.05.019 Wizemann, 2010, Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy, Kidney Int, 77, 1098, 10.1038/ki.2009.477 De Vriese, 2021, Safety and efficacy of vitamin k antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial, J Am Soc Nephrol, 32, 1474, 10.1681/ASN.2020111566 De Vriese, 2015, Dose-finding study of rivaroxaban in hemodialysis patients, Am J Kidney Dis, 66, 91, 10.1053/j.ajkd.2015.01.022 Siontis, 2018, Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States, Circulation, 138, 1519, 10.1161/CIRCULATIONAHA.118.035418 Mavrakanas, 2020, Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation, Clin J Am Soc Nephrol, 15, 1146, 10.2215/CJN.11650919